Drugs · acquisition-cost intelligence
Triasil
Triamcinolone acetonide· ingredient triamcinoloneCorticosteroids· TRIAMCINOLONE ACETONIDE 1 mg/g; TRIAMCINOLONE ACETONIDE 5 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.11513
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other triamcinolone products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| triamcinolone acetonide | $0.07238 | −$0.04270 |
| Dermavyx | $0.08272 | −$0.03240 |
| Triamcinolone Acetonide | $0.18453 | +$0.06940 |
| NYSTATIN AND TRIAMCINOLONE ACETONIDE | $0.23054 | +$0.11540 |
| triamcinolone acetonide | $0.27895 | +$0.16380 |
| nystatin and triamcinolone acetonide | $0.28013 | +$0.16500 |
| TRIAMCINOLONE ACETONIDE | $0.31654 | +$0.20140 |
| 24 Hour Nasal Allergy | $0.74946 | +$0.63430 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 24% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.